Cargando…

The efficacy of EGFR-tyrosine kinase inhibitor in non-small cell lung cancer patients with synchronous brain metastasis: a real-world study

BACKGROUND/AIMS: The optimal treatment (Tx) for epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients with brain metastasis (BM) remains to be determined. METHODS: A retrospective review was conducted on 77 NSCLC patients with synchronous BM who underwent first-l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Choi, Jin-Hyuk, Choi, Yong Won, Lee, Hyun Woo, Kang, Seok Yun, Jeong, Geum Sook, Ahn, Mi Sun, Oh, Young-Taek, Noh, O kyu, Kim, Se-Hyuk, Roh, Tae Hoon, Sheen, Seung Soo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Association of Internal Medicine 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8925938/ https://www.ncbi.nlm.nih.gov/pubmed/35167736 http://dx.doi.org/10.3904/kjim.2021.315

Ejemplares similares

Trastuzumab-based palliative chemotherapy for HER2-positive gastric cancer: a single-center real-world data
por: Kim, Tae-Hwan, et al.
Publicado: (2021)

Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
por: Choi, Yong Won, et al.
Publicado: (2017)

Molecular subtypes of small cell lung cancer transformed from adenocarcinoma after EGFR tyrosine kinase inhibitor treatment
por: Hwang, Soohyun, et al.
Publicado: (2021)

The role of third-line chemotherapy in recurrent or metastatic gastric cancer: A cohort study with propensity score matching analysis
por: Choi, Yong Won, et al.
Publicado: (2018)

Combination versus single-agent as palliative chemotherapy for gastric cancer
por: Choi, Jin-Hyuk, et al.
Publicado: (2020)

Analysis of thromboembolic events in patients with non-small cell lung cancer who received adjuvant chemotherapy: single-center real-world data
por: Kim, Tae-Hwan, et al.
Publicado: (2022)

Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors
por: Choi, Yu-ra, et al.
Publicado: (2022)

The role of surgical resection before palliative chemotherapy in advanced gastric cancer
por: Choi, Yong Won, et al.
Publicado: (2019)

Continuous Renal Replacement Therapy for Acute Renal Failure in Patients with Traumatic Brain Injury
por: Park, Chang-Yong, et al.
Publicado: (2016)

Predictive Efficacy of Low Burden EGFR Mutation Detected by Next-Generation Sequencing on Response to EGFR Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Carcinoma
por: Kim, Hye Sook, et al.
Publicado: (2013)

Endovascular Repair Using Suture-Mediated Closure Devices and Balloon Tamponade following Inadvertent Subclavian Artery Catheterization with Large-Caliber Hemodialysis Catheter
por: Park, Taek Kyu, et al.
Publicado: (2016)

Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer
por: Ji, Wonjun, et al.
Publicado: (2013)

Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2013)

The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation
por: Lee, Youngjoo, et al.
Publicado: (2016)

Contribution of p53 in sensitivity to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
por: Jung, Sangyong, et al.
Publicado: (2021)

Real-world clinical evidence of lazertinib use in acquired EGFR T790M mutated non-small cell lung cancer
por: Park, Sehhoon, et al.
Publicado: (2023)

Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis
por: Byeon, Seonggyu, et al.
Publicado: (2016)

Correction: Role of IGF-Binding Protein 3 in the Resistance of EGFR Mutant Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitors
por: Choi, Yun Jung, et al.
Publicado: (2019)

EGFR Mutation–Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis
por: Kim, Hongsik, et al.
Publicado: (2023)

Quantification of epidermal growth factor receptor (EGFR) mutation may be a predictor of EGFR‐tyrosine kinase inhibitor treatment response
por: Park, Ha Young, et al.
Publicado: (2016)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
por: Huang, Lihua, et al.
Publicado: (2015)

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
por: Yang, Jiyoul, et al.
Publicado: (2018)

EGFR C797S as a Resistance Mechanism of Lazertinib in Non-small Cell Lung Cancer with EGFR T790M Mutation
por: Park, Sehhoon, et al.
Publicado: (2020)

Clinical Characteristics and Continued Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Administration in EGFR-mutated Non-Small Cell Lung Cancer with Skeletal Metastasis
por: Hong, Sook-Hee, et al.
Publicado: (2016)

Real-World Approach for Molecular Analysis of Acquired EGFR Tyrosine Kinase Inhibitor Resistance Mechanisms in NSCLC
por: Hondelink, Liesbeth M., et al.
Publicado: (2021)

Supramaximal Resection for Glioblastoma: Redefining the Extent of Resection Criteria and Its Impact on Survival
por: Roh, Tae Hoon, et al.
Publicado: (2023)

Real-world analysis of first-line afatinib in patients with EGFR-mutant non-small cell lung cancer and brain metastasis: survival and prognostic factors
por: Kim, Jehun, et al.
Publicado: (2023)

Imaging of EGFR and EGFR Tyrosine Kinase Overexpression in Tumors by Nuclear Medicine Modalities
por: Mishani, Eyal, et al.
Publicado: (2008)

Clinical activity of the EGFR tyrosine kinase inhibitor osimertinib in EGFR-mutant glioblastoma
por: Makhlin, Igor, et al.
Publicado: (2019)

Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
por: Suda, Kenichi, et al.
Publicado: (2021)

Synchronous Onset of Symmetrically Associated Extragenital Lichen Sclerosus and Vitiligo on both Breasts and the Vulva
por: Kwon, In Hyuk, et al.
Publicado: (2015)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy
por: Chang, Hyun, et al.
Publicado: (2016)

Characterization of acquired receptor tyrosine–kinase fusions as mechanisms of resistance to EGFR tyrosine–kinase inhibitors
por: Xu, Haiyuan, et al.
Publicado: (2019)

Synchronous occurrence of gastrointestinal stromal tumor and intrahepatic cholangiocarcinoma: A case report
por: NAM, SEUNG-JOO, et al.
Publicado: (2015)

AXL and MET receptor tyrosine kinases are essential for lung cancer metastasis
por: Choi, Yun Jung, et al.
Publicado: (2019)

A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13
por: Yoo, Kwai Han, et al.
Publicado: (2019)

Neurological Change after Gamma Knife Radiosurgery for Brain Metastases Involving the Motor Cortex
por: Park, Chang-Yong, et al.
Publicado: (2016)

Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors
por: Amelia, Tasia, et al.
Publicado: (2022)

Randomized Trial of First-Line Tyrosine Kinase Inhibitor With or Without Radiotherapy for Synchronous Oligometastatic EGFR-Mutated Non-Small Cell Lung Cancer
por: Wang, Xiao-Shan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_si081c22mes7eu64cu0kuq97f3